104265-89-6

Basic information

• Product Name: 3-Cyclohexene-1-carboxylic acid, 6-(chlorocarbonyl)-, methyl ester, (1S-cis)- (9CI)
• Synonyms: 3-Cyclohexene-1-carboxylic acid, 6-(chlorocarbonyl)-, methyl ester, (1S-cis)- (9CI)
• CAS NO: 104265-89-6
• Molecular Formula: C₉H₁₁ClO₃
• Molecular Weight: 202.63484
• Product Categories: ACIDHALIDE
• Mol File: 104265-89-6.mol
• Article Data: 9

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 3-Cyclohexene-1-carboxylic acid, 6-(chlorocarbonyl)-, methyl ester, (1S-cis)- (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Cyclohexene-1-carboxylic acid, 6-(chlorocarbonyl)-, methyl ester, (1S-cis)- (9CI)(104265-89-6)
• EPA Substance Registry System: 3-Cyclohexene-1-carboxylic acid, 6-(chlorocarbonyl)-, methyl ester, (1S-cis)- (9CI)(104265-89-6)

Safety Data

• Hazardous Substances Data: 104265-89-6(Hazardous Substances Data)

Upstream product

• 935-79-5 cis-1,2,3,6-tetrahydrophthalic anhydride 
• 146388-94-5 (1S,2R)-2-formyl-1-methoxycarbonylcyclohex-4-ene 
• 93603-11-3 1-methyl hydrogen 1,2-cis-1,2-cyclohex-4-ene dicarboxylate 
• 4841-84-3 dimethyl cis-1,2,3,6-tetrahydrophthalate 
• 31139-02-3 (1R,6S)-6-methoxycarbonyl-3-cyclohexene-1-carboxylic acid 

Downstream Products

• 65376-03-6 (3aR,7aS)-1,3,3a,4,7,7a-hexahydroisobenzofuran-1-one 
• 149564-35-2 (1S,2R)-2-Formyl-cyclohexanecarboxylic acid methyl ester 
• 15679-28-4 ((1R,6R)-6-(hydroxymethyl)cyclohex-3-enyl)methanol 
• 6493-77-2 (R)-(+)-methyl 3-cyclohexene-1-carboxylate 
• 104265-90-9 (1S,6R)-Methyl 6-Hydroxymethyl-3-cyclohexene-1-carboxylate 
• 127943-95-7 methyl (1R,3R)-3-(tert-butyldimethylsilyloxy)cyclohex-4-ene-1-carboxylate 
• 1026073-45-9 methyl (1R,3R,4R,5S)-3-(tert-butyldimethylsilyloxy)-4-hydroxy-5-methylcyclohexane-1-carboxylate 
• 1026073-50-6 methyl (1R,3R,4R,5S)-4-O-(2,3,4-tri-O-benzyl-6-deoxy-α-L-galactopyranosyl)-3-O-(tert-butyldimethylsilyl)-3,4-dihydroxy-5-methylcyclohexane-1-carboxylate 
• 1026074-30-5 (1R,2R,4R,6S)-2-tert-butyldimethylsilyloxy-4-hydroxymethyl-6-methylcyclohexyl 2,3,4-tri-O-benzyl-6-deoxy-α-L-galactopyranoside 
• 1026074-32-7 (1R,2R,4R,6S)-2-tert-butyldimethylsilyloxy-4-chloromethyl-6-methylcyclohexyl 2,3,4-tri-O-benzyl-6-deoxy-α-L-galactopyranoside 
• 1026074-33-8 (1R,2R,4R,6S)-2-tert-butyldimethylsilyloxy-4,6-dimethylcyclohexyl 2,3,4-tri-O-benzyl-6-deoxy-α-L-galactopyranoside 
• 1026074-34-9 (1R,2R,4R,6S)-2-hydroxy-4,6-dimethylcyclohexyl 2,3,4-tri-O-benzyl-6-deoxy-α-L-galactopyranoside 
• 5709-98-8 (R)-cyclohex-3-enecarboxylic acid 
• 54911-89-6 (1R,5R)-methyl-5-hydroxycyclohex-3-enecarboxylate 

Relevant articles and documents

Cinchona alkaloid derivative modified Fe3O4nanoparticles for enantioselective ring opening of: Meso -cyclic anhydrides

In the present work, the molecular framework of quinidine was modified at the methoxy functional group of the C6′ carbon of the quinoline moiety with a long-chain carboxylic acid group (-COOH) and it was used as a capping agent during the synthesis of Fe3

Pre-organization of the core structure of E-selectin antagonists

A new class of N-acetyl-dglucosamine (GlcNAc) mimics for Eselectin antagonists was designed and synthesized. The mimic consists of a cyclohexane ring substituted with alkyl substituents adjacent to the linking position of the fucose moiety. Incorporation into E-selectin antagonists led to the test compounds 8 and the 2'-benzoylated analogues 21, which exhibit affinities in the low micromolar range. By using saturation transfer difference (STD)-NMR it could be shown that the increase in affinity does not result from an additional hydrophobic contact of the alkyl substituent with the target protein E-selectin, but rather from a steric effect stabilizing the antagonist in its bioactive conformation. The loss of affinity found for antagonists 10 and 35 containing a methyl substituent in a remote position (and therefore unable to support to the stabilization of the core) further supports this hypothesis. Finally, when a GlcNAc mimetic containing two methyl substituents (52 and 53) was used, in which one methyl was positioned adjacent to the fucose linking position and the other was in a remote position, the affinity was regained.

Methods of use of glycomimetics with replacements for hexoses and n-acetyl hexosamines

Methods are provided for using a compound to treat, for example, endothelial dysfunction including vascular abnormalities. More specifically, methods are described for using an oligosaccharide compound or glycomimetic compound wherein a cyclohexane derivative is incorporated in either.